Hi Everyone...we're about to get started. Please introduce yourselves in the chat box.

OK

Philisiwe Dlamini from Eswatini

Tiffany Lillie

Michael Cassell, FHI 360 LINKAGES / EpiC

Hally Mahler

Parinita Bhattacharjee

Be sure to write to "All panelists and attendees" in the chat, not to "all panelists"

Jeff Eaton, Imperial College London

Virginia Macdonald WHO HQ

Siti Sulami, LINKAGES Indonesia

Tobi Saidel

Kinh Nguyen, Imperial College London

Robyn Dayton, FHI 360

Athena Richardson, FHI 360 LINKAGES/EPIC

Loveleen Bansi-Matharu, UCL, London

Sujata Bijou, IntraHealth International

Mary Mahy, UNAIDS

Meg DiCarlo, FHI 360

Eva Canoutas, IntraHealth Intl

Kenoakae Pule - Pact Linkages/KPIF projects

Caitlin Loehr, IntraHealth International

Parsa Sanjana, FHI 360

Salesa Abuga, PATH -Kenya

Curious how modeling would be impacted with the inclusion of PrEP, including on-demand PrEP (now including all attendees).

Cameroon Case Study Question: Given the gap on addressing the needs of clients of female sex workers and MSMs, would you recommend one or more of the following: (1) strengthening the health systems of the Government of Cameroon, private sector, and NGOs, (2) increasing or focusing on a rights based approach for advocacy for those that are clients of FSWs and MSMs, and (3) a media campaign help to raise awareness on the gap (or would working with traditional media and social media lead to backlash from the general population due to cultural discrimination, and related stigma and violence)? How could donors working in other non HIV sectors support reduction of the gap for a multisectoral approach?

Has the impact of injecting drug use and harm reduction coverage been included in these models?

I also wonder about including PrEP? And impact of diagnosis?

Just FYI, Greg's not using slides; just making remarks.

Now that the models are there, would it be easy to replicate the same analysis in other countries quickly?

I want to encourage everyone to stay a couple minutes past 9 am. We'll have the panel address a couple questions and for those questions we can't address I'd encourage you to contact the presenters directly.

Should Greg's slides be advancing?

Greg is not using slides.

what is the limitation of MOT model?

what's difference between MOT and AEM?

Hi Pari, to your question re: "would it be easy to replicate same analyses". Yes, we are in a much better place to do this now with rigorous data review, bias adjustments, and input of local data re: KP and wider population (prevalence over time, prevention gaps).

USAID might be able to act on an HIV Integration imperative if we had leadership at the highest level of GH that considers all work in the agency and how it can be leveraged to have impact.

Let's do 1 or 2

Sorry, me again. DO you think this model would work to model impact globally or in different regions?

I can follow up with panelists if no time to answer

Have to jump, but thanks so much to Tisha for organizing, and to the presenters as well. Very interesting, and would welcome more of these data-driven discussions in the near future.

Thanks!

Thanks everyone!